Insider Selling: XOMA Co. (NASDAQ:XOMA) Major Shareholder Sells $13,069,366.20 in Stock

XOMA Co. (NASDAQ:XOMA) major shareholder Bvf Partners L. P/Il sold 500,742 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

XOMA Price Performance

XOMA stock opened at $26.26 on Friday. The company’s 50-day moving average price is $27.91 and its two-hundred day moving average price is $28.09. XOMA Co. has a 12 month low of $19.50 and a 12 month high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a market cap of $309.34 million, a P/E ratio of -7.55 and a beta of 0.92.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.05. The business had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.66 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. On average, analysts anticipate that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of XOMA

Several institutional investors and hedge funds have recently modified their holdings of XOMA. BNP Paribas Financial Markets raised its stake in XOMA by 95.0% during the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the last quarter. Rhumbline Advisers increased its position in XOMA by 18.1% during the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 1,699 shares in the last quarter. State Street Corp lifted its stake in XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Finally, Barclays PLC lifted its stake in XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

XOMA has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $123.00 target price on shares of XOMA in a report on Tuesday, January 7th. StockNews.com upgraded XOMA from a “sell” rating to a “hold” rating in a research note on Thursday, January 16th.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.